瑞舒伐他汀短期治疗急性冠脉综合征患者血清MMP-9水平变化的研究

摘要

Objective:To study the short-term rosuvastatin in patients with acute coronary syndrome (ACS), serum metalloproteinase levels in its impact, and its clinical efficacy. Method: In our hospital 66 cases of patients with ACS as the treatment group, select the other 65 cases of healthy volunteers as control group. Basis of symptomatic patients with ACS in addition to the treatment given rosuvastatin for 6 weeks, compared before and after treatment in patients with ACS, and with the control group MMP-9, plasminogen aggregation inhibitor agent (PAI-1) differences. Result: ACS patients serum MMP-9, PAI-1 levels were significantly higher (P＜0.05). After 6 weeks of treatment in patients with ACS serum MMP-9, PAI-1 were significantly reduced (P＜0.05), but still greater than the control group (P ＜0.05). Conclusion: Rosuvastatin in patients with ACS with lower MMP-9 reduces the role of inflammation.%目的 探讨瑞舒伐他汀在短期治疗急性冠脉综合征(ACS) 患者中对其血清金属蛋白酶水平变化的影响.方法 选择我院住院的ACS 患者66 例作为治疗组,另选健康志愿者65 例作为对照组.ACS 患者除接受基础对症治疗外给予瑞舒伐他汀6周,比较ACS 患者治疗前后,及与对照组的MMP-9 、纤溶酶原聚合剂抑制因子(PAI-1) 的差异.结果 ACS 患者治疗前血清MMP-9 、PAI-1 含量明显高于对照组(P<0.05),经过6周治疗后ACS 患者的血清MMP-9 、PAI-1 均显著减小(P<0.05),但依旧大于对照组(P<0.05).结论 瑞舒伐他汀具有降低ACS 患者MMP-9,降低炎症反应的作用.